An analysis of healthcare demand, clinical innovation, and the business economics of companies represented in Bolna’s Healthcare Leaders portfolio.
Demand, innovation, and delivery
Healthcare is not one industry or one business model. The same patient needs can support medicines, devices, scientific tools, care providers, and consumer health—but each captures value differently.
1Long-Duration Healthcare Demand
Demographic change and chronic disease shape patient needs. The resulting economics depend on coverage, clinical capacity, pricing, and continuity of care.
1.1Population Aging & Care Intensity
Population aging can increase demand for skilled nursing and post-acute care, directly relevant to The Ensign Group. HCA Healthcare also treats older patients, but its hospital and ambulatory volumes reflect a broader clinical and local-market case mix. The businesses operate at different points along the care continuum.
The Ensign Group depends on facility-level occupancy, care quality, staffing, and payer mix. HCA Healthcare depends more on hospital case mix, procedure volumes, labor productivity, and capital-intensive clinical capacity. Sustained demand need not produce the same margins.
Wage pressure, care-quality requirements, public-payer reimbursement, and capacity constraints can undermine returns despite rising treatment needs.
- The Ensign GroupSkilled nursing and post-acute care
- HCA HealthcareHospitals and ambulatory care
1.2Chronic Disease & Metabolic Health
Diabetes and obesity create linked needs for medicines, long-term disease management, and monitoring. Eli Lilly and Company and Novo Nordisk develop competing metabolic-disease treatments, while Abbott Laboratories supplies glucose-monitoring technology. Drug franchises and device platforms address related patients but capture value through different pathways.
For pharmaceutical manufacturers, value creation depends on outcomes, market access, manufacturing capacity, patient persistence, and competitive differentiation. Monitoring systems depend on clinical utility, repeat sensor use, and payer coverage. Growing demand does not determine relative returns across these business models.
Treatment competition, safety monitoring, pricing negotiations, supply investment, and payer restrictions may change drug profitability; reimbursement and device competition can independently affect monitoring economics.
- Eli Lilly and CompanyMetabolic and chronic-disease medicines
- Abbott LaboratoriesDiabetes monitoring and diagnostics
- Novo NordiskDiabetes and obesity medicines
2Clinical Innovation & Medical Technology
Research, evidence, and technology can change standards of care. Investment outcomes depend on how new treatments and tools are adopted, reimbursed, and defended competitively.
2.1Research-Led Medicines
Research-led pharmaceutical businesses combine established product franchises with the continual need for clinical innovation. Roche, Novartis, AbbVie, Sanofi, AstraZeneca PLC, Merck & Co., Inc., and Bristol Myers Squibb span differentiated medicines across oncology, immunology, metabolic and cardiorenal disease, vaccines, and rare conditions. Johnson & Johnson combines Innovative Medicine with a distinct MedTech business. Scientific discovery alone does not guarantee successful commercialization.
Value depends on product differentiation, regulatory approval, intellectual property, reliable supply, market access, and portfolio renewal. AstraZeneca PLC illustrates a diversified therapeutic portfolio in which oncology, biopharmaceuticals, and rare disease have distinct innovation and commercialization dynamics. Merck & Co., Inc. also has an animal-health business with a different demand base. Johnson & Johnson spans pharmaceuticals and medical devices, but these operations should not be treated as a single homogeneous earnings engine.
Late-stage clinical setbacks, safety findings, concentration in major products, loss of exclusivity, pricing regulation, and acquisition integration can change returns independently of underlying healthcare demand.
- RocheInnovative medicines and diagnostics
- NovartisResearch-led innovative medicines
- AbbVieSpecialty medicines and immunology
- SanofiSpecialty medicines and vaccines
- AstraZeneca PLCOncology, biopharma and rare diseases
- Merck & Co., Inc.Innovative medicines, vaccines and animal health
- Bristol Myers SquibbInnovative medicines and cell therapy
- Johnson & JohnsonInnovative Medicine and MedTech
2.2Diagnostics, Laboratory Tools & Monitoring
Roche and Abbott Laboratories offer diagnostic and monitoring products. Thermo Fisher Scientific provides laboratory instruments, consumables, and specialty diagnostics; Danaher Corporation spans diagnostics, life-science instruments, and bioprocessing technologies. These businesses support distinct testing, research, and manufacturing workflows rather than a single uniform market.
Test volumes, installed instruments, replacement reagents and consumables, and ongoing sensor use can generate repeat demand. Danaher Corporation exemplifies how instruments and workflow integration can support subsequent purchases of proprietary consumables and service; revenue still depends on test utilization and customer budgets. Pricing and margins depend on clinical utility, procurement, reimbursement, and competitive alternatives.
Procurement pressure, changes in testing pathways, reimbursement, instrument competition, and laboratory investment cycles may limit the benefits of expanding diagnostic demand.
- RocheInnovative medicines and diagnostics
- Abbott LaboratoriesDiabetes monitoring and diagnostics
- Thermo Fisher ScientificScientific tools and specialty diagnostics
- Danaher CorporationDiagnostics, instruments and consumables
2.3Surgical, Orthopedic & Interventional Technology
Intuitive Surgical provides robotic-assisted surgical systems; Boston Scientific develops interventional devices; and Stryker supplies orthopedic implants, surgical equipment, and robotic-assisted orthopedic technology. Johnson & Johnson also operates a diversified MedTech business. Their clinical markets overlap, but procurement cycles, installed-platform economics, and procedure-linked demand differ.
Intuitive Surgical combines installed systems with instruments and services, while interventional and orthopedic suppliers rely on procedure-dependent devices and implants. Providers weigh clinical evidence, surgeon training, workflow efficiency, acquisition costs, and reimbursement.
Clinical evidence, device safety, implant competition, hospital budgets, and procedural reimbursement can affect adoption and profitability in different ways.
- Intuitive SurgicalRobotic-assisted surgical systems
- Boston ScientificMinimally invasive interventional devices
- StrykerSurgical and orthopedic technology
- Johnson & JohnsonMedical devices and surgical technology
2.4Acute Care, Surgical Workflows & Sterile Processing
Getinge AB supplies technologies for intensive care, operating rooms, sterile processing, and life-science production. Its Acute Care Therapies, Surgical Workflows, and Life Science activities address distinct clinical and industrial workflows. This differs from Intuitive Surgical’s surgical-robotics platform and the procedure-linked devices of Boston Scientific and Stryker: not all hospital technology is driven by the same purchasing decision or procedure volume.
Capital equipment can create an installed base for consumables, upgrades, maintenance, and training. Acute-care demand depends on clinical need and installed-system use; operating-room systems depend on hospital procurement and workflow adoption; life-science equipment also depends on pharmaceutical and bioprocessing investment. High-margin consumables do not eliminate cyclicality in large equipment orders. Getinge’s October 2026 interim report described differing conditions across these business areas.
Medical-device quality and regulatory compliance, product recalls, clinical reliability, hospital capital budgets, consumable utilization, procurement deferrals, and life-science investment cycles. Reported adjusted margins can also reflect temporary currency or tariff effects.
- Getinge ABAcute care and clinical infrastructure
Official issuer website; a Healthcare Leaders profile may be linked here once published.
2.5Vision Care, Optical Technology & Retail
EssilorLuxottica combines ophthalmic lenses, eyewear brands, optical retail networks, and vision-care technology. It operates at the intersection of clinical needs, consumer preferences, and branded distribution. Its economics differ from hospital-purchased devices and from pharmaceutical reimbursement models.
Lens innovation, retail reach, manufacturing integration, prescription demand, and brand strength can support recurring customer relationships. However, prescription products, premium frames, and retail services have different pricing power and purchasing behavior.
Consumer spending, fashion cycles, retail execution, optical competition, reimbursement where applicable, product innovation, and regulatory scrutiny can affect earnings even when demand for vision correction remains resilient.
- EssilorLuxotticaLenses, eyewear brands and optical retail
3Healthcare Delivery, Capacity & Access
Care providers, medicine suppliers, pharmacy services, and nutrition businesses respond to patient needs through distinct clinical and commercial channels.
3.1Care Networks & Operating Productivity
UnitedHealth Group operates health benefits and Optum services; HCA Healthcare operates hospitals and ambulatory facilities; and The Ensign Group provides post-acute care. Their roles overlap across the care pathway, but medical-cost exposure, operating risk, and capital needs differ.
Health plans manage benefits, medical costs, and utilization; hospitals manage staffing, procedures, and clinical capacity; post-acute providers manage occupancy and facility-level care. Systemwide efficiency does not necessarily translate into equal returns for each participant.
Medical-cost inflation, public policy, provider labor supply, reimbursement rules, and regulatory oversight can shift value between payers, operators, and patients.
- UnitedHealth GroupHealth benefits, services and data
- HCA HealthcareHospitals and ambulatory care
- The Ensign GroupSkilled nursing and post-acute care
3.2Research Tools & Biopharma Manufacturing
Thermo Fisher Scientific supplies laboratory instruments, consumables, and outsourced biopharma services. Danaher Corporation provides life-science and bioprocessing tools, while Lonza Group provides contract development and manufacturing for pharmaceutical and biotechnology customers. These are related but distinct positions in the pharmaceutical research and production value chain.
Instrument purchases and recurring consumables differ from contracted manufacturing capacity. Danaher Corporation’s bioprocessing products and research tools can be embedded in customer workflows; Thermo Fisher Scientific also participates in instruments, consumables, and outsourced services. By contrast, Lonza Group must fill and operate specialized manufacturing facilities effectively.
Research funding, bioprocess investment cycles, customer concentration, development delays, program cancellations, manufacturing quality, and facility utilization may create earnings volatility even as therapeutic research advances.
- Thermo Fisher ScientificScientific tools and specialty diagnostics
- Lonza GroupContract development and manufacturing
- Danaher CorporationBioprocessing and life-science tools
3.3Generics, Biosimilars & Pharmacy Services
Sandoz Group develops and supplies generic and biosimilar medicines, while UnitedHealth Group operates pharmacy-benefit and pharmacy-care services through Optum Rx. Generic and biosimilar manufacturing differs from pharmacy-benefit administration, and neither should be conflated with Cencora’s wholesale distribution model.
Sandoz Group relies on regulatory expertise, efficient manufacturing, and dependable supply. Optum Rx combines pharmacy-benefit management with specialty and home-delivery pharmacy services; its economics depend on contracts, service fees, pharmacy networks, and changing purchasing models.
Generic price pressure, biosimilar competition, tendering, and supply quality affect manufacturers; transparency rules, reimbursement policy, contracting incentives, and fee-model changes affect pharmacy services.
- Sandoz GroupGeneric and biosimilar medicines
- UnitedHealth GroupOptum Rx pharmacy services
3.4Pharmaceutical Distribution & Supply-Chain Economics
Cencora distributes branded, specialty, and generic medicines through wholesale and related commercialization networks. Pharmaceutical distributors connect manufacturers, pharmacies, providers, and treatment settings. This is distinct from manufacturing drugs or administering pharmacy benefits.
High product throughput and broad networks create scale but generally carry lower margins than patented therapeutics. Value depends on efficient logistics, inventory and working-capital management, reliable service, specialty distribution capabilities, and contractual terms.
Customer concentration, contract repricing, reimbursement changes, product availability, regulatory compliance, inventory exposure, and litigation can impair returns despite substantial distribution volumes.
- CencoraPharmaceutical wholesale and specialty distribution
3.5Nutrition & Consumer Health
Abbott Laboratories sells infant, pediatric, and adult nutrition products, including products for specialized dietary needs. This business differs from medicines and devices in its purchasing decisions, retail channels, and consumer exposure.
Product development, trusted brands, clinical use, supply reliability, and distribution access can support repeat purchasing. Nutrition differs from patented drugs because brand competition and retail channels play a larger role.
Product safety, manufacturing quality, consumer affordability, retailer dynamics, and changes in clinical recommendations can affect demand and margins.
- Abbott LaboratoriesNutrition and diversified healthcare products
Company profiles illustrate relevant business activities. Some companies appear in more than one theme.
Where the economics diverge
Three company-level comparisons show why similar healthcare needs can produce different revenue models, investment risks, and outcomes.
01
Drug value differs across discovery, exclusivity, and distribution
Innovators such as Roche, Novartis, AstraZeneca PLC, Merck & Co., Inc., and Bristol Myers Squibb depend on differentiated therapies and portfolio renewal. Sandoz Group competes in generics and biosimilars; Cencora operates distribution networks. The same therapeutic demand produces fundamentally different margins, capital needs, and risk exposures.
02
Clinical technology meets distinct purchasing systems
Intuitive Surgical, Boston Scientific, Stryker, and Johnson & Johnson’s MedTech operations serve clinical procedures and hospital purchasers. Getinge AB adds acute-care devices, surgical infrastructure, and sterile processing, where consumables and services may recur even when capital-equipment purchases slow. EssilorLuxottica has a different vision-care model based on lenses, brands, and optical retail. Patient need alone does not determine adoption, pricing power, or channel economics.
03
Service breadth does not eliminate execution risk
Thermo Fisher Scientific and Danaher Corporation span research instruments, diagnostics, and recurring consumables, while Lonza Group develops and manufactures medicines under client contracts. Installed-platform demand is different from manufacturing-capacity utilization. Funding cycles, customer concentration, quality requirements, and execution remain material risks.
Eleven healthcare operating models
A qualitative comparison of eleven distinct operating models represented across Healthcare Leaders.
| Business model | Primary value driver | Key sensitivity | Illustrative companies |
|---|---|---|---|
| Innovative medicines | Clinical differentiation, exclusivity, launches, pipeline renewal | Clinical failure, patent loss, pricing and access | Roche · Novartis · AbbVie · Sanofi · AstraZeneca PLC · Merck & Co., Inc. · Bristol Myers Squibb · Johnson & Johnson |
| Diagnostics, tools & monitoring | Clinical utility, installed instruments, testing and sensors | Reimbursement, procurement and changing workflows | Abbott Laboratories · Roche · Thermo Fisher Scientific · Danaher Corporation |
| Surgical & interventional technology | Adoption, procedure volumes, training and installed platforms | Hospital budgets, device safety and competition | Intuitive Surgical · Boston Scientific · Stryker · Johnson & Johnson |
| Acute care & hospital infrastructure | Installed equipment, clinical reliability, consumables, service, and sterile processing | Quality compliance, capital budgets, procurement, recalls, and life-science cycles | Getinge AB |
| Vision care & optical retail | Lens technology, branded eyewear, retail reach and repeat vision needs | Consumer demand, retail costs, competition and product innovation | EssilorLuxottica |
| Care providers | Care quality, patient volumes, case mix and local operations | Staffing, reimbursement and clinical capacity | HCA Healthcare · The Ensign Group |
| Health benefits & pharmacy services | Medical-cost management, networks, and pharmacy services | Medical costs, policy, regulation and contracting | UnitedHealth Group |
| Nutrition & consumer health | Trusted products, clinical use, supply and repeat purchase | Brand competition, affordability and product quality | Abbott Laboratories |
| Research tools & manufacturing services | Specialist science, manufacturing capacity and customer programs | Research funding, utilization and execution | Thermo Fisher Scientific · Danaher Corporation · Lonza Group |
| Generics & biosimilars | Regulatory capability, reliable supply and cost efficiency | Competition, tenders and drug-price pressure | Sandoz Group |
| Pharmaceutical distribution | Wholesale throughput, efficient logistics, specialty access and contract execution | Thin margins, working capital, contract terms and regulatory exposure | Cencora |